A California-based investment firm manages several innovative venture capital funds. The funds invest in early, growth, and expansion-stage technology and life science companies. The firm closed its second fund in July 2015 and principally invests in early and growth-stage investments in Series A, B, and C preferred equity rounds with other top-tier institutional and corporate investors. The firm will lead investments with their third fund. The investment size is variable and dependent on the company’s capitalization plan and future capital requirements. The firm currently focuses its’ investment activities in parts of the western USA that are under-served by venture capital such as Southern California, the southwest, and northwest. The firm is actively seeking institutional investment limited partners and new investment opportunities.

In the Life Sciences area, the firm seeks to invest in medical device, product, diagnostics, specialty pharma, and healthcare IT. The firm is opportunistic in terms of sub-sectors and indications. The firm generally seeks clinical stage therapeutics that are at least Phase II, and diagnostics and medical devices that are very close to or with FDA approval.

The funds are led by a seasoned VC with a track record of investing. The firm generally co-invests with other top-tier institutional and corporate investors, and will work with companies to help them organize an investment syndicate. The firm seeks investment opportunities in rapidly growing companies with world-class products and solutions that address major market needs; along with talented leadership, management teams, and boards with deep industry experience and track records of success.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects that have significant entry barrier and can address unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity investment firm based in Israel seeks early stage companies to form and establish, as well as investing to bridge the gap between late stage companies in Israel and companies with sales activity in the U.S. and Europe (“platforms”). The firm currently has a $130M fund that the firm is both allocating out of and raising with an aim of $300M. For early-stage companies, the firm typically invests from a few $100K to a couple million per company; for platforms/late stage, the firm usually invest up to $25M per company; and may syndicate for more capital if required. The firm invests in two platform deals and one early-stage company per year. The firm is interested in companies based in the U.S., Europe, or Israel.

The firm is interested in medical devices only. The firm is agnostic to disease indication and is not interested in pharmaceuticals. The firm may be interested in the diagnostics and digital health space, though is quite selective in these opportunities. For early-stage opportunities, the firm is interested in disruptive technologies at IP and/or preclinical stage. In the past, the firm has invested in diabetes, obesity, heart failure, structural heart, pulmonary hypertension, currently looking at neurology and urology, and is open to new areas of focus. For late-stage/Platform companies, the firm is interested in those that have sales between $30-70M as well as sales organization in different fields within the company’s space.

For early stage investment, the firm does not have a management team requirement, as it has the capability to invest in technology and IP alone and build the team around it. The firm is very active post investment by taking more than just a board seat, the firm gets very involved in the company formation and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new $125M life sciences venture fund affiliated with a leading research university is focused on early-stage healthcare technology in seed, Series A/B rounds. The firm is opportunistic geographically, though has preference for companies based in the USA.

The firm is interested in therapeutics, medical devices, and healthcare IT. The firm is opportunistic with particular interest in neuroscience, oncology, osteopathy, and ophthalmology products. In healthcare IT, the firm is interested in AI and augmented reality in life sciences. The firm seeks preclinical to clinical stage products.

The firm does not have a specific management team requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm is dedicated to funding private, early stage, pre-clinical and clinical neuroscience therapeutics and technologies for neurological and psychiatric diseases and disorders. The firm invests in Seed and Series A rounds, typically allocating $1-10 million USD for each deal. The firm looks for deals globally and plans to make 8-10 investments in the upcoming year. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on treating those with psychiatric and neurological diseases. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered. The firm is primarily interested in therapeutics and technologies that are pre-clinical or in development.

The firm sometimes prefers to take a board seat in companies in which they invest and prefers management teams that have a strong technical background within the clinical neuroscience area of focus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global medical corporation headquartered in the USA is interested in making acquisitions and distribution agreements in the medical device sector, and does not invest in equity financing rounds. The firm typically makes 6-12 deals per year, including both early stage and mature companies. The firm will consider medical device opportunities worldwide.

The firm is interested in novel medical devices that fit into their existing clinical areas: anesthesia, respiratory devices, venous access, interventional devices (primarily in cardiology), surgical devices (with a focus on minimally invasive access and closure), urology, and OEM. In general, the firm prefers that products already have regulatory approval, but this is not an absolute requirement. The firm mostly focuses on devices that use a 510k pathway.

The firm focuses on products that have strong IP portfolios, good gross margins (65% or over) and which have the potential to really occupy an important market position. The firm has a global presence and therefore focuses on acquisitions and global rights rather than regional distribution.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital company founded in 2005 manages just under $50 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Healthcare IT products, Life Science Research Tools and Medical Devices with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.